eyeforpharma Barcelona 2018

eyeforpharma13 - 15 March 2018, Barcelona, Spain.
eyeforpharma Barcelona is an annual pilgrimage for pharma's executives who want to map their future commercial success. Now it has become the place to map a different journey, that of our customers and patients. Gain their trust and serve as their guiding light towards better outcomes for all.

One eyeforpharma Barcelona. 9 in-depth commercial pharma conferences on the key issues of 2018 and beyond. This year we will bring you unrivalled expertise, patient insights, real-world data - the building blocks to deliver innovative and complete healthcare solutions, to make a real difference to the lives of patients and customers.

1. A Vision for the Future
2. Commercial Model Innovation
3. Talent and Diversity
4. Patient Partnerships
5. Advances in Customer Engagement
6. Digital Innovation and Analytics
7. Sales Force Effectiveness
8. Interactive Sessions - you lead the discussion
9. Medical Affairs

Why you can't miss Barcelona 2018

Barcelona is not a normal conference. Our mission is to create the mass movement we need across the pharma industry.

We must ask ourselves is it possible for a pharma company to be a credible, go-to source of health knowledge? Is it possible to be trusted, respected and admired? Despite having all the resources, expertise and reach, pharmaceutical companies are still a long way from this. To get there, each company must better appreciate the value it provides - and to have a greater vision for the value it can provide.

2018 will guarantee:

  • Collaborative setting: Our aim to ensure your key stakeholder are present to advance partnerships with healthcare, technology, patient and patient association
  • An Inspiring Agenda: As you undergo a commercial evolution we will cover 9 themes, provide intimate workshops and keynote sessions to help direct your journey
  • 1200+ in attendance: If you are looking for one commercial meeting to attend in 2018, Barcelona will be sure to give you the most senior networking opportunities possible
  • NO Sales Pitch: this is an independently researched event committed to equipping you with the techniques and expertise to drive your business. You will take-away actionable insights proven to drive your commercial strategy
  • More Than 80 Executive-level Thought Leaders sharing their experience and knowledge. Take this opportunity to transform your organisation, become truly customer-centric and improve healthcare outcomes.

Join the most forward-thinking speakers from across Europe including C-Level, VPs and Industry leaders from J&J, Bayer Pharmaceuticals, Lilly Bio Medicines, Teva, Takeda and MSD. This is the ideal place to ensure your commercial strategy is prepared for 2018 and beyond.

World Pharma News readers can benefit from an exclusive discount - save €200 using the unique discount code WPN200 when you register online here.

For further information, please visit:
http://www.eyeforpharma.com/barcelona/

About eyeforpharma
Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry's health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the centre.

Most Popular Now

Top 20 breaking World Pharma News of 2017

We are proud to announce the top 20 most popular breaking World Pharma News from 2017. Have a wonderful 2018 new(s) year filled with health, happiness, and spectacular su...

Roche and Ignyta reach definitive merger agreement

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. (NASDAQ: RXDX) today announced they have entered into a definitive merger agreement for Roche to fully acquire Ignyta ...

Antidepressant may help combat the course of multi…

The antidepressant clomipramine may also alleviate symptoms of multiple sclerosis (MS), specifically in its progressive form, i.e. when it occurs without relapses or remi...

Novartis advances head-to-head superiority trials …

Novartis announced today the initiation of SURPASS, a head-to-head clinical trial of Cosentyx® (secukinumab) versus proposed biosimilar adalimumab** in ankylosing spondyl...

Distinct human mutations can alter the effect of m…

Every person has a unique DNA sequence in their genome. Now researchers from the University of Copenhagen and the MRC Laboratory of Molecular Biology in Cambridge have tr...

FDA updates the label of Tasigna to reflect that c…

The U.S. Food and Drug Administration today updated the product label for the cancer drug Tasigna (nilotonib) to include information for providers about how to discontinu...

Zika remains a research and public health challeng…

Since 2016, when Zika was declared by the World Health Organization as a public health emergency of international concern, the virus has become established in more than 8...

FDA approves novel gene therapy to treat patients …

The U.S. Food and Drug Administration today approved Luxturna (voretigene neparvovec-rzyl), a new gene therapy, to treat children and adult patients with an inherited for...

Diabetes drug 'significantly reverses memory loss…

A drug developed for diabetes could be used to treat Alzheimer's after scientists found it "significantly reversed memory loss" in mice through a triple method of action...

Try exercise to improve memory, thinking

For patients with mild cognitive impairment, don't be surprised if your health care provider prescribes exercise rather than medication. A new guideline for medical pract...

Arthritis drug could help treat advanced skin canc…

Treatment for the most deadly form of skin cancer could be more effective if combined with a well-known drug for rheumatoid arthritis, new research has shown. The study, ...

Novartis Kisqali® received FDA Breakthrough Therap…

Novartis today announced Kisqali® (ribociclib) received US Food and Drug Administration (FDA) Breakthrough Therapy designation for initial endocrine-based treatment of pr...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]